Price
No data yet.
Social Signal Score
Analyst Ratings
49 analystsRevenue
$4.39B-32.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard D. Francis
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 32,008
- Beta
- 0.84
- Country
- IL
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.88
Financials
Revenue
$4.39B-32.3%Net Income
$233.00MEBITDA
$545.00MFree Cash Flow
$121.00M-88.9%EPS (diluted)
$0.20Shares Outstanding (diluted)
1.18B+16.6%Operating Expenses
$1.30BCash & Debt
$4.08BReturn of Capital
$0.00Revenue by Segment (annual)
$17.26BDividend per Share
$0.09Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $17.26B | $1.41B | $1.23 |
| 2024 | $16.54B | $-1.64B | $-1.45 |
| 2023 | $15.85B | $-559.00M | $-0.50 |
| 2022 | $14.93B | $-2.45B | $-2.20 |
| 2021 | $15.88B | $417.00M | $0.38 |
| 2020 | $16.66B | $-3.99B | $-3.64 |
| 2019 | $16.89B | $-999.00M | $-0.92 |
| 2018 | $18.85B | $-2.15B | $-2.11 |
| 2017 | $22.39B | $-16.27B | $-16.01 |
| 2016 | $21.90B | $329.00M | $0.07 |
| 2015 | $19.65B | $1.59B | $1.84 |
| 2014 | $20.27B | $3.06B | $3.58 |
| 2013 | $20.31B | $1.27B | $1.49 |
| 2012 | $20.32B | $1.96B | $2.25 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TEVA's reported EPS growth of -4.5% a year over 13 years.
- EPS in 5 years
- $0.98
- Implied price
- $24.46
- Return from $38.54
- -8.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $12.16 — -68.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -14.5% | -24.3% | -21.1% | -18.3% | -15.8% | -13.6% |
| -9.5% | -19.9% | -16.4% | -13.5% | -10.9% | -8.5% |
| -4.5% | -15.5% | -11.8% | -8.7% | -5.9% | -3.5% |
| 0.5% | -11.0% | -7.2% | -3.9% | -1.0% | 1.6% |
| 5.5% | -6.6% | -2.6% | 0.9% | 3.9% | 6.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
0-100.00%Social Signal Score
Mentions (51)
- Newsbusinesswire.com·9h ago·Negative
TEVA Investors Have Opportunity to Join Teva Pharmaceutical Industries Limited Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $TEVA--TEVA Investors Have Opportunity to Join Teva Pharmaceutical Industries Limited Fraud Investigation with SBS Law.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor
View source ↗ - Newsglobenewswire.com·11d ago·Positive
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
View source ↗ - Newsfool.com·16d ago·Negative
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? Teva improved margins significantly. The pharmaceutical company has paid down net debt.
View source ↗ - Newszacks.com·18d ago·Neutral
Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.
View source ↗ - Newsmarketbeat.com·18d ago·Negative
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-drug sales, particularly generic REVLIMID.
View source ↗ - Newsseekingalpha.com·19d ago·Neutral
Teva Pharmaceutical Industries Limited (TEVA) Q3 2026 Earnings Call Transcript Teva Pharmaceutical Industries Limited ( TEVA ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Richard Francis - President, CEO & Director Eric Hughes - Executive VP of Global R&D and Chief Medical Officer Eliyahu Kalif - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institut…
View source ↗ - Newszacks.com·19d ago·Negative
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsreuters.com·19d ago·Positive
Teva Pharmaceutical Q3 profit gain beats estimates Teva Pharmaceutical Q3 profit gain beats estimates
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…part of its Pivot to Growth strategy TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd.
View source ↗ - Newsreuters.com·20d ago·Neutral
Teva to discontinue mid-stage neurodegenerative disorder study Teva to discontinue mid-stage neurodegenerative disorder study
View source ↗ - Newsseekingalpha.com·22d ago·Neutral
Teva: I Still See Upside After A Massive Rally Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and several high-potential pipeline drugs could add $5.5B–$9B in annual peak sales, driving significant revenue growth. Financials are markedly improved: debt halved since 2017, cash balance rising, and revenue rebounding, positioning TEVA for further upside.
View source ↗ - Newszacks.com·24d ago·Neutral
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
View source ↗ - Newszacks.com·41d ago·Neutral
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
View source ↗ - Newsseekingalpha.com·44d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
View source ↗ - Newsmarketbeat.com·44d ago·Negative
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA Teva Pharmaceutical Industries NYSE: TEVA said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for schizophrenia.
View source ↗ - Newsglobenewswire.com·44d ago·Negative
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and
View source ↗ - Newsglobenewswire.com·51d ago·Positive
…h Tourette Syndrome PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data inc…
View source ↗ - Newsglobenewswire.com·51d ago·Positive
… Pediatric Patients PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The re…
View source ↗ - Newsbusinesswire.com·52d ago·Negative
…iosimilar Candidates INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- #Fasenra--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referen…
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer.
View source ↗ - Newszacks.com·54d ago·Negative
Teva's Branded Drugs Take Center Stage in Its Growth Strategy Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
…t), a Biosimilar to Xgeva® (denosumab) TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva® (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents w…
View source ↗ - Newsglobenewswire.com·60d ago·Neutral
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
View source ↗ - Newsglobenewswire.com·60d ago·Neutral
Teva Releases Q3 2026 Aide Memoire TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.
View source ↗ - Newsseekingalpha.com·60d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·60d ago·Negative
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings Teva Pharmaceutical Industries NYSE: TEVA is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference.
View source ↗ - Newsseekingalpha.com·61d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript
View source ↗ - Newsmarketbeat.com·61d ago·Neutral
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline Teva Pharmaceutical Industries NYSE: TEVA Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operations.
View source ↗ - Newsglobenewswire.com·65d ago·Negative
… in Older Patients PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
View source ↗ - Newsglobenewswire.com·65d ago·Neutral
…d Healthcare Costs PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizoph…
View source ↗ - Newsglobenewswire.com·65d ago·Positive
…ophrenia in Adults PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-'749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-'749 as a once-monthly subcutaneous long-acting injectab…
View source ↗ - Newsschaeffersresearch.com·67d ago·Neutral
Most Active Options Report: FPS, TEVA, AFL These three stocks are seeing some of the most unusual options volume today
View source ↗ - Newsmarketbeat.com·69d ago·Neutral
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform Teva Pharmaceutical Industries NYSE: TEVA CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·69d ago·Negative
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars Teva Pharmaceutical Industries NYSE: TEVA said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet.
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy PARSIPPANY, N.J. and TEL AVIV, Israel, Sept.
View source ↗ - Newsglobenewswire.com·73d ago·Negative
…Successful Pricing of $4.9 billion (Equivalent) Senior Notes TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the “Conditional Redempt…
View source ↗ - Newsglobenewswire.com·76d ago·Neutral
Teva Announces Launch of Offering of Senior Notes TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutic…
View source ↗ - Newsschaeffersresearch.com·80d ago·Positive
Outperforming Pharma Stock Still Has Upside Potential Teva Pharmaceuticals Industries (NYSE:TEVA) is moving 2.9% lower to trade at $36.41, pulling back from its Aug. 27, nearly nine-year high of $38.36.
View source ↗ - Newsseekingalpha.com·81d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript
View source ↗ - Newsmarketbeat.com·81d ago·Neutral
Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key measures of intestinal damage.
View source ↗ - Newsreuters.com·81d ago·Negative
Teva's immune disorder drug meets main goal in mid-stage trial Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a mid-stage trial.
View source ↗ - Newsglobenewswire.com·81d ago·Negative
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Teva reports positive Phase 2a results for Teva-discovered TEV '408, showing significant prevention of gluten-induced intestinal damage in celiac disease.
View source ↗ - Newsglobenewswire.com·83d ago·Negative
…ARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities. “Teva appreciates the opportunity to wor…
View source ↗ - Newszacks.com·83d ago·Neutral
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
View source ↗ - Newsglobenewswire.com·86d ago·Negative
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approv
View source ↗ - Newszacks.com·94d ago·Neutral
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.
View source ↗ - Newszacks.com·95d ago·Neutral
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock? Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.
View source ↗ - Newsglobenewswire.com·95d ago·Negative
…ARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advan…
View source ↗
Earnings
Wed, Jan 27(in 2 months)
Consensus estimate $0.70 per share
Typical surprise +10.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.86 vs $0.72beat
- Wed, Jul 29$0.02 vs $0.08miss
- Wed, Apr 29$0.53 vs $0.50beat
- Wed, Jan 28$0.96 vs $0.65beat
- Wed, Nov 5$0.78 vs $0.68beat
- Wed, Jul 30$0.66 vs $0.63beat
Estimates and results for TEVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TEVA officers and directors.
- Bought
- —
- Sold
- $53.4m
0 trades
31 trades
- Sabag Marksold
- Daniell Richardsold
- Francis Richard Dsold
- Daniell Richardsold
- Weiss Amirsold
- Weiss Amirsold
- Weiss Amirsold
- Sabag Marksold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 2, 2020 (19d later)Buy$15,001 - $50,000
- Donna Shalalahouse · FL27 · disclosed May 15, 2020 (8d later)Sell$1,001 - $15,000
- David Eugene Pricehouse · NC04 · disclosed Jul 11, 2019 (22d later)Sell$1,001 - $15,000
- Patty Murraysenate · WA · disclosed Jun 22, 2017 (7d later)Sell$1,001 - $15,000
- Angus Kingsenate · ME · disclosed Nov 10, 2016 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
